ReviewCureus2025
Impact of Lifestyle Modifications Along With Pharmacological Treatment of Heart Failure: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changes in NT-proBNP Levels According to SGLT2 Inhibitor Use in Patients Hospitalized for Acute Heart Failure Decompensation: A Prospective Cohort Study.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. While pharmacological therapy is foundational, lifestyle modifications are increasingly recognised for their complementary role. This narrative review explores the synergistic effects of lifestyle interventions, combined with pharmacological treatment, in HF management. A literature search (2000-2025) was conducted using PubMed, Scopus, Cochrane, and Google Scholar, to identify studies on integrative approaches to HF care. Lifestyle changes, such as dietary modification, exercise, weight management, smoking and alcohol cessation, and psychosocial support, enhance the efficacy of standard therapies, improve quality of life, and reduce hospitalisations. Integration with medications, like renin-angiotensin-aldosterone system (RAAS) inhibitors, beta-blockers, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, shows improved neurohormonal balance, reduced inflammation, better endothelial function, and delayed cardiac remodelling. However, socioeconomic and cultural barriers challenge real-world implementation. Combining lifestyle interventions with pharmacotherapy provides a holistic, patient-centred strategy for HF management. Future efforts should focus on personalised care, multidisciplinary teams, and policy support, to improve adherence and outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.